An antibody biomarker was recently discovered that identifies people with chronic skeletal muscle disease and severe heart muscle involvement.
A survey of more than 600 people with myositis from the US, Korea, and Sweden identified 5 aspects of living with the disease that are most important to patients.
A new study found that people with scleroderma who have muscle weakness due to the accumulation of fibrous tissue in their muscles, are at risk for severe disease outcomes including death from heart disease.
A collaborative effort between Rheumatology and Oncology offers guidance to doctors treating patients for inflammatory arthritis caused by treatment with “immune checkpoint inhibitors”, a type of cancer therapy.
A study lead by Lisa Christopher-Stine, M.D., M.P.H. identified “Hiker’s Feet” as a new skin finding in some patients with inflammatory muscle disease (myositis).
Younger patients with a specific form of myositis associated with antibodies to a protein called HMGCR have a worse prognosis than older patients.
Medical record review of patients admitted to the Johns Hopkins Hospital over 20-years, revealed that pneumocystis jiroveci pneumonia infection is a rare but persistent risk for patients with rheumatic diseases.
The study provides new evidence that a bacterium known to cause chronic inflammatory gum infections also triggers the inflammatory autoimmune response characteristic of chronic, joint-destroying rheumatoid arthritis (RA). The new findings have important implications for prevention and treatment of RA.
A new biomarker discovered using cutting-edge technologies is found in people who develop scleroderma and cancer within a short period of time.